Drug discovery firm expands into new BioCity building

Nottingham-based drug discovery company XenoGesis is set to move into BioCity Nottingham’s new Discovery Building, after receiving grant funding from the Government’s Regional Growth Fund and the University of Derby Invest to Grow Programme.

XenoGesis will be taking 5,500 sq ft on the first floor of the Discovery Building which was officially opened in June 2017. The new space will provide an 83% increase on the firm’s current premises the Innovation Building.

XenoGesis is working with MCI Consulting’s Brian McInnis, a facilities and project manager, who is overseeing the fit-out of the laboratories and office space. The move is expected to complete in June.

Richard Weaver, managing director of XenoGesis, said: “We have grown year on year and our current space within BioCity Nottingham’s Innovation Building is now at capacity. Further expansion would have resulted in staff being split up around the building, or in different buildings, which we wanted to avoid. The recently opened Discovery Building provides us with the ideal space for the next chapter in XenoGesis’ growth.”

Chief executive of BioCity, Glenn Crocker, said: “Since starting out at BioCity, XenoGesis has gone from strength to strength. This expansion is yet more evidence of the success of this great company and, I’m sure, the start of a new phase of growth. We are proud to have XenoGesis as an active member of the BioCity community and to be an investor in this high-quality business.”

Mark Wheddon, head of delivery at Invest to Grow added: “We are delighted to continue to support XenoGesis with their growth plans and the development of new services to benefit customers, which will see the company expand and the creation of new jobs.”